Literature DB >> 3104056

Antagonist capacities of nifedipine, captopril, phenoxybenzamine, prostacyclin and indomethacin on cyclosporin A induced impairment of rat renal function.

H Dieperink, P P Leyssac, H Starklint, K A Jørgensen, E Kemp.   

Abstract

Experimental evidence indicates that cyclosporin A (CyA) nephrotoxicity is due to renal arteriolar constriction, reducing renal blood flow, glomerular filtration rate (GFR), and delivery of tubular fluid from the end of the proximal tubule to the loop of Henle. The proximal tubular fractional reabsorption (PFR) is increased. Therefore, the impact on renal function of vasodilating agents was studied in rats given CyA. Conscious catheterized rats and clearance techniques were used. In acute experiments a preexisting CyA-nephrotoxicity was resistant to infusion of phenoxybenzamine, prostacyclin, captopril, nifedipine and indomethacin. Concomitant treatment with captopril and CyA did not improve renal function, while concomitant treatment with CyA and nifedipine improved GFR to 1.13 +/- 0.34 ml min-1 g-1 kidney weight (gKW) (n = 19, P less than 0.05), as compared to CyA and placebo treated controls (n = 12, 0.83 +/- 0.32 ml min-1 g-1 KW). Nifedipine also reduced FPR (88.6 +/- 5.1% vs. 83.2 +/- 5.6%. P less than 0.01), and increased lithium clearance from 99 +/- 54 to 184 +/- 64 microliters min-1 g-1 KW (P less than 0.001). The results are further evidence that CyA nephrotoxicity includes renal vasoconstriction, and indicates that calcium entry blockade is nephroprotective in the case of CyA toxicity.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3104056     DOI: 10.1111/j.1365-2362.1986.tb02175.x

Source DB:  PubMed          Journal:  Eur J Clin Invest        ISSN: 0014-2972            Impact factor:   4.686


  7 in total

1.  Does nifedipine ameliorate cyclosporin A nephrotoxicity?

Authors:  J Feehally; J Walls; N Mistry; T Horsburgh; J Taylor; P S Veitch; P R Bell
Journal:  Br Med J (Clin Res Ed)       Date:  1987-08-01

2.  Influence of nicardipine on renal function and plasma cyclosporin in renal transplant patients.

Authors:  M Kessler; P Netter; E Renoult; B Jonon; J M Mur; P Trechot; B Dousset
Journal:  Eur J Clin Pharmacol       Date:  1989       Impact factor: 2.953

3.  Changes in the venous compliance by bradykinin and angiotensin II and its significance for the vascular effects of cyclosporine-A.

Authors:  E Müller-Schweinitzer
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1988-12       Impact factor: 3.000

4.  Calcium entry and 5-HT2 receptor blockade in oliguric ischaemic acute renal failure: effects of levemopamil in conscious rats.

Authors:  H J Kramer; J Rosberg; A Bäcker; H Meyer-Lehnert
Journal:  Br J Pharmacol       Date:  1996-03       Impact factor: 8.739

Review 5.  The pathophysiology of Sandimmune (cyclosporine) in man and animals.

Authors:  J Mason
Journal:  Pediatr Nephrol       Date:  1990-09       Impact factor: 3.714

6.  Difference between aortic and renal vascular reactivity in cyclosporin A treated rats and the effect of cicletanine.

Authors:  E O Mikkelsen; S H Poulsen; N C Nyborg; N Korsgaard; J Sehested
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1992-03       Impact factor: 3.000

Review 7.  Do calcium channel blockers have renal protective effects?

Authors:  G P Reams
Journal:  Drugs Aging       Date:  1994-10       Impact factor: 3.923

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.